RESEARCH Open Access

# Check for

# Mechanical power normalized to predicted body weight is associated with mortality in critically ill patients: a cohort study

Yanhong Zhu<sup>1</sup>, Wenyong Peng<sup>2</sup>, Shuai Zhen<sup>2</sup> and Xiaofeng Jiang<sup>2\*</sup>

#### **Abstract**

**Background:** Mechanical power (MP), defined as the amount of energy produced by mechanical ventilation and released into the respiratory system, was reportedly a determining factor in the pathogenesis of ventilator-induced lung injury. However, previous studies suggest that the effects of MP were proportional to their involvement in the total lung function size. Therefore, MP normalized to the predicted body weight (norMP) should outperform the absolute MP value. The objective of this research is to determine the connection between norMP and mortality in critically ill patients who have been on invasive ventilation for at least 48 h.

**Methods:** This is a study of data stored in the databases of the MIMIC–III, which contains data of critically ill patients for over 50,000. The study involved critically ill patients who had been on invasive ventilation for at least 48 h. norMP was the relevant exposure. The major endpoint was ICU mortality, the secondary endpoints were 30-day, 90-day mortality; ICU length of stay, the number of ventilator-free days at day 28.

**Result:** The study involved a total of 1301 critically ill patients. This study revealed that norMP was correlated with ICU mortality [OR per quartile increase 1.33 (95% CI 1.16–1.52), p < 0.001]. Similarly, norMP was correlated with ventilator-free days at day 28, ICU length of stay. In the subgroup analysis, high norMP was associated with ICU mortality whether low or high Vt (OR 1.31, 95% CI 1.09–1.57, p = 0.004; OR 1.32, 95% CI 1.08–1.62, p = 0.008, respectively). But high norMP was associated with ICU mortality only in low PIP (OR 1.18, 95% CI 1.01–1.38, p = 0.034).

**Conclusion:** Our findings indicate that higher norMP is independently linked with elevated ICU mortality and various other clinical findings in critically ill patients with a minimum of 48 h of invasive ventilation.

**Keywords:** Critically ill, Mortality, Mechanical ventilation, Ventilator-induced lung injury, Mechanical power normalized to predicted body weight

# **Background**

When performing surgery or in critically ill patients, mechanical ventilation is a vital component of supportive treatment since it preserves respiratory function and minimizes respiratory effort [1–3]. However, in mechanical ventilation, the mechanical force produced

by the interaction between the ventilator and respiratory tract, can damage the lungs. This is known as ventilator-induced lung injury (VILI) [4-6].

The severity of VILI is determined by the ventilator settings [7]. Variables, such as tidal volume (Vt), respiratory rate (RR), and positive end-expiratory pressure (PEEP), are set directly on the ventilator by the clinician [1]. Others, such as peak pressure (PIP) and plateau pressure, rely on the patient's respiratory system or their interaction with the ventilator. Up to now, all these factors have been assessed separately

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication in a credit line to the data.

<sup>\*</sup>Correspondence: 719085915@qq.com

<sup>&</sup>lt;sup>2</sup> Department of Anesthesiology, Jinhua Municipal Central Hospital, 365 Renmin East Road, Jinhua, Zhejiang, China

Zhu et al. BMC Anesthesiology (2021) 21:278 Page 2 of 9

[8]; however, VILI may be unified into a single variable as mechanical power (MP), which is energy per unit of time applied to the respiratory system by the ventilator [7, 9, 10]. Energy generated by the mechanical ventilator is related to Vt, RR, PEEP, plateau pressure, and flow [9], demonstrating that MP can be calculated accurately through combining Vt, plateau pressure, PEEP, and RR [7]. The introduction of this "power equation" shows MP has a stronger modulating effect on VILI than individual ventilator settings owing to the incorporation of multiple aspects of mechanical ventilation [7, 9].

Increases in MP measured on the second day after intensive care unit (ICU) admission was correlated with increased hospital mortality in a recent study on 8207 critically ill mechanically ventilated patients [11]. In addition, previous studies [7, 8] have suggested that the effects of MP were proportional to their involvement in the total lung function size. We hypothesized that the effect of MP relative to lung size can be calculated by MP normalized to the predicted body weight (norMP) [12]. This is similar to normalizing tidal volume to predicted body weight (PBW) [13]. Therefore, norMP should outperform the absolute MP value. In acute respiratory distress (ARDS) patients, Coppola et al. [14] showed that elevated norMP led to increased mortality. However, few studies have determined the association between norMP and the outcomes of critically ill mechanically ventilated patients.

The objective of this study was to explore the prognostic role of mechanical power normalized to the predicted body weight in the clinical outcomes of intensive care patients.

## **Methods**

#### Data source

The Massachusetts Institute of Technology's Laboratory for Computational Physiology maintains the Multiparameter Intelligent Monitoring in Intensive Care III (MIMIC III, V.1.4) database, which includes data on over 50,000 patients admitted to the intensive care unit at Beth Israel Deaconess Medical Center between 2001 and 2012 [15]. We attended a training course on 'protecting human subjects' in order to apply for access to the database.

The establishment of the database was approved by the institutional review boards of the Massachusetts Institute of Technology (Cambridge, MA) and Beth Israel Deaconess Medical Center (Boston, MA). The author Jiang extracted the data for this study after passing the National Institutes of Health's online training course (certification number: 9322422).

#### Population selection criteria

In total, 58,976 intensive care unit (ICU) patients were recorded in the MIMICIII database, of these, we included in our study patients who were older than 16 at the time of their initial admission and who underwent invasive ventilation for a minimum of 48 consecutive hours. Patients were excluded if they met the criteria: had incomplete ventilatory variables to calculate MP and norMP, received pressure support ventilation, had >1% missing data, were extubated, or had died during the first 48 h. We used only data from the patient's initial ICU admission or initial hospitalization.

#### Data extraction

The structured query language (SQL) was used to extract data from the database, and included tidal volume (Vt), positive end–expiratory pressure (PEEP), peak inspiratory pressure (PIP), RR, and the inspired fraction of oxygen (FiO<sub>2</sub>). The following equation was used to calculate mechanical power [7, 11]:

 $MP(J/min) = 0.098 \times Vt \times RR \times (PIP - \Delta P \times 0.5)$ , where the driving pressure ( $\Delta P$ ) = PIP - PEEP [16].

norMP ( $\times 10^{-3}$  J/min/kg)=MP/PBW [12], where PBW was the predicted body weight calculated by using the equation as used in previous studies of ventilation [17]:

$$PBW = 50.0 + 0.91$$
 (height [cm]  $- 152.4$ ) in males,

$$PBW = 45.5 + 0.91$$
 (height [cm]  $- 152.4$ ) in females.

Due to the fact that the patients provided multiple measurements, the mean values obtained during the second 24h was used. The norMP in the second day of ventilation was chosen because during the first 24h usually mechanical ventilation is subjected to several changes and may result in more noise. Moreover, a previous study has shown that there was a decrease in MP from the first to the second 24h of ventilation [11].

The following demographic data (using first 24h of admission data) were collected: age, gender, ethnicity (white, black, or other), height, weight, comorbidities, and disease severity scores (Acute Physiology and Chronic Health Evaluation [APACHE] III) [18, 19]. Vital signs and laboratory measurements were captured as mean values in the first day of ventilation.

#### Clinical outcome

To gather information about ICU patients' status, the follow-up followed from ICU admission and ended at death. The major endpoint was ICU mortality, the secondary endpoints included 30-day, 90-day mortality; ICU length of stay (ICU\_LOS), the number of ventilator-free days

Zhu et al. BMC Anesthesiology (2021) 21:278 Page 3 of 9

at day 28 (VFD\_28, specified as the days from effective weaning to day 28; patients who died prior to weaning were considered to have no ventilator-free days).

# Statistical analyses

Continuous variables are presented in the tables as the median with interquartile ranges. The required Mann-Whitney U test, or Kruskal– Wallis test, was applied. Chisquared test or Fisher's exact test was used for categorical variables, which are presented as a percentage. Patients were categorized into groups according to ICU mortality.

The median and interquartile range of norMP was used to classify all patients. For all outcomes, univariate and multivariate regression were used to account for potential confounding variables. Relevant covariates known to predict outcome were entered into the model including age, sex, ethnicity, BMI, admission type, comorbidities, APACHE, heart rate, MAP, SpO<sub>2</sub>, temperature, pH, PaO<sub>2</sub> / FiO<sub>2</sub>, PaCO<sub>2</sub>. These variables were selected due to their clinical relevance. The final models were built using a stepwise backward elimination method with a significance level of 0.05. Additionally, subgroup analyses were


conducted to determine the relationship between norMP and the primary outcome according to the Vt and PIP levels. According to the concepts of protective ventilation [20] and a previous study [21], and the data was empirically adjusted to define low Vt as Vt  $< 8 \, \text{mL/PBW}$  and low PIP as PIP  $< 30 \, \text{cmH}_2\text{O}$ .

Statistical significance was described as a two-sided p < 0.05. SPSS software was used for all statistical analysis (SPSS-22.0; IBM Corp., Armonk, NY, USA).

#### Results

Finally, 1301 patients fulfilled the requirements for the study (Fig. 1). Table 1 summarizes the demographic characteristics of survivors and non-survivors. norMP was significantly lower for survivors (222.1(161.3–288.0)  $\times\,10^{-3}\,\mathrm{J/min/kg}$ ) than non-survivors (245.4(183.8–333.4)  $\times\,10^{-3}\,\mathrm{J/min/kg}$ ) (p<0.001), but the MP has no significant difference across the entire cohort.

Across the entire cohort, norMP had a median of  $226.5 \times 10^{-3}$  J/min/kg and an interquartile range of  $166.5-301.0 \times 10^{-3}$  J/min/kg, respectively. All patients were divided into quartile according to their norMP as follows: less than  $166.4 \times 10^{-3}$  J/min/kg, quartile 1,



Zhu et al. BMC Anesthesiology (2021) 21:278 Page 4 of 9

**Table 1** Comparisons of demographics between survivors and non–survivors

Age, years  61.3 (48.5-74.0)  68.3 (56.0-79.0)  Male gender  508 /936 (54.3)  191 / 365 (52.3)  Weight, kg  82 / (69.0-99.0)  78.0 (65.0-92.0)  Height, cm  170 (163-178)  108 (160-176)  BML kg/m²  28.4 (243-33.3)  26.8 (23.2-32.1)  PBW, kg  Admission type  Selective  82 / 936 (8.8)  11 / 365 (3.0)  Emergency  836 / 936 (9.3)  349 / 365 (9.6)  Urgent  18 / 936 (1.9)  5 / 365 (1.4)  Ethnicity  White  64 / 7936 (9.1)  81 / 365 (3.1)  81 / 365 (3.1)  81 / 365 (3.1)  Comorbidites  CHF  Cardiac arrhythmias  21 / 936 (22.6)  110 / 365 (3.0)  Diabetes  5 / 936 (5.7)  30 / 365 (2.1)  Diabetes  5 / 936 (1.8)  110 / 365 (3.0)  Diabetes  6 / 939 (27.8)  Neurological condition  139 / 936 (14.9)  Chronic pulmonary condition  215 / 936 (21.1)  Severity of illness  APACHE III  5 (38-69)  89 / 365 (9.9)  89 / 365 (9.9)  180 / 365 (9.9)  181 / 365 (3.7)  Severity of illness  APACHE III  5 (38-69)  89 (36-99)  78.0 (68-8.18)  79 (68-8.8)  PEPE cmH <sub>2</sub> O  71 (61-10)  PIP, cmH <sub>2</sub> O  71 (61-10)  PIP, cmH <sub>2</sub> O  72 (77-11)  96 (68-117)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (68-61)  10 (10 (10 - 17)  10 (68-61)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (68-61)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (10 (10 - 17)  10 (10 (10 (10 - 17)  10 (10 (10 (10 (10 (10 (10 (10 (10 (10 (	line characteristics	Survivors (n=936)	Non-survivors (n = 365)	<i>p</i> value
Male gender         508 / 936 (54.3)         191 / 365 (52.3)           Weight, kg         827 (690-990)         780 (655-9-20.0)           Height, cm         170 (163-178)         168 (160-176)           BML kg/m²         28.4 (24.3-33.9)         26.8 (23.2-32.1)           PBW, kg         30.9 (34.7-73.1)         31.7 (52.5-7.18)           Admission type         Selective         82 / 936 (8.8)         11 / 365 (3.0)           Emergency         38 / 936 (9.9)         349 / 365 (9.5)           Urgent         18 / 936 (1.9)         223 / 365 (61.1)           Ethnicity         2White         447 / 936 (69.1)         223 / 365 (61.1)           Black         85 / 936 (91.1)         31 / 365 (3.5)           Other         204 / 936 (71.8)         111 / 365 (30.4)           Comorbidities         212 / 936 (22.6)         110 / 365 (30.1)           CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         33 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Neurological condition         139 / 936 (13.9)         87 / 365 (21.5)           Liver condition         50	years	61.3 (48.5–74.0)	68.3 (56.0–79.0)	< 0.001
Welght, kg         82.7 (69.0-99.0)         78.0 (65.0-92.0)           Height, cm         170 (163-178)         168 (160-176)           BM, kg/m²         28.4 (243-33.9)         62.8 (223-221)           PBW, kg         63.9 (54.7-73.1)         61.7 (525-71.8)           Admission type         32.936 (8.8)         11.7 365 (3.0)           Energency         83.6 /936 (89.3)         349 / 365 (95.6)           Urgent         18.7 936 (91.9)         5.365 (1.4)           Ethnicity         223 / 365 (6.11)           White         647/936 (69.1)         31 / 365 (3.0)           Other         204 / 936 (9.1)         31 / 365 (3.0)           Comorbidities         212 / 936 (22.6)         110 / 365 (30.1)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         35 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (18.3)         56 / 356 (13.3)           Diabetes         260 / 936 (77.8)         119 / 365 (32.6)           Neurological condition         315 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)		508 / 936 (54.3)		0.527
Height.cm				< 0.001
BMI, kg/m²         28.4 (24.3-33.9)         26.8 (23.2-32.1)           PBW, kg         63.9 (4.7-73.1)         61.7 (52.5-71.8)           Admission type         Selective         82.9 (38.8)         11/365 (3.0)           Emergency         836 / 936 (89.3)         349 / 365 (95.6)           Urgent         18 / 936 (1.9)         5 / 365 (1.4)           Ethnicity         Ferricance         Ferricance           White         647 / 936 (69.1)         31 / 365 (8.5)           Black         85 / 936 (9.1)         31 / 365 (8.5)           Other         204 / 936 (21.8)         111 / 365 (30.4)           Comorbidities         T         T           CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         50 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal faiture         160 / 936 (17.1)         57 / 365 (20.5) <td></td> <td></td> <td></td> <td>0.015</td>				0.015
PBW. kg         63.9 (54.7-73.1)         61.7 (52.5-71.8)           Admission type           Selective         82/936 (8.8)         11/365 (3.0)           Emergency         836/936 (89.3)         349/365 (9.56)           Urgent         18/936 (1.9)         5/365 (1.4)           Ethnicity         White         647/936 (69.1)         223/365 (61.1)           Black         85/936 (9.1)         31/365 (8.5)           Other         204/936 (21.8)         111/365 (30.4)           Comorbidities         CHF         CHF         CARRIAGE (8.1)         78/365 (21.4)           Cardiac arrhythmias         212/936 (22.6)         110/365 (30.1)           Valvular disease         53/936 (57.7)         30/365 (82.2)           Hypertension         143/936 (15.3)         56/365 (15.3)           Diabetes         260/936 (27.8)         119/365 (32.6)           Neurological condition         139/936 (14.9)         46/365 (12.6)           Chronic pulmonary condition         215/936 (23.0)         88/365 (24.1)           Everal failure         160/936 (17.1)         75/365 (20.5)           Liver condition         95/936 (10.1)         50/365 (13.7)           Severity of illness         37/267 (10.2)         <				0.001
Admission type         Selective         82 / 936 (8.8)         11 / 365 (3.0)           Emergency         836 / 936 (89.3)         349 / 365 (95.6)           Urgent         18 / 936 (1.9)         5 / 365 (1.4)           Ethnicity         232 / 365 (61.1)         Black         85 / 936 (9.1)         31 / 365 (8.5)           Other         204 / 936 (21.8)         111 / 365 (30.4)           Comorbidities         5 / 70 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Liver condition         95 / 936 (10.1)         50 / 365 (13.7)           Severity of illness         8         8           APACH EIII         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         89 (75-103)         89 (75-103) <td>_</td> <td></td> <td></td> <td>0.026</td>	_			0.026
Selective         82/936 (8.8)         11/365 (3.0)           Emergency         836/936 (89.3)         349/365 (95.6)           Urgent         18/936 (1.9)         5/365 (1.4)           Ethnicity         White         647/936 (69.1)         223/365 (61.1)           Black         85 / 936 (9.1)         31 / 365 (8.5)           Other         204 / 936 (21.8)         111/365 (30.4)           Comorbidities         T         T           CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (80.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Liver condition         95 / 936 (10.1)         50 / 365 (13.7)           Severity of Illness         1         87 (79 – 10)         89 (75 – 10)           Heart rate, bpm         89 (75 – 103)         89		,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0.001
Emergency         836 / 936 (89.3)         349 / 365 (95.6)           Urgent         18 / 936 (1.9)         5 / 365 (1.4)           Ethnicity         ****           White         647 / 936 (69.1)         223 / 365 (61.1)           Black         85 / 936 (9.1)         31 / 365 (8.5)           Other         204 / 936 (21.8)         1111 / 365 (30.4)           Comorbidities         ***         ***           CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (82.)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Everity of illness         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         89 (77-103)         89 (75-103)           MAP, mHlg         82 (76-91)         30 / 36 (-3.7)         36 (-9.9)	<b>,</b> '	82 / 936 (8.8)	11 / 365 (3.0)	
Urgent         18 / 936 (1.9)         5 / 365 (1.4)           Ethnicity           White         647 / 936 (69.1)         223 / 365 (61.1)           Black         85 / 936 (9.1)         31 / 365 (8.5)           Other         204 / 936 (21.8)         111 / 365 (30.4)           Comorbidities         170 / 936 (18.1)         78 / 365 (21.4)           CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         260 / 936 (7.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Liver condition         95 / 936 (10.1)         50 / 365 (13.7)           Severity of illness         40 / 36 (17.1)         75 / 365 (20.5)           APACHE III         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         98 (75-91)         89 (75-103) <td< td=""><td></td><td></td><td></td><td></td></td<>				
Ethnicity         White         647/936 (69.1)         223/365 (61.1)           Black         85/936 (91.)         31/365 (8.5)           Other         204/936 (21.8)         111/365 (30.4)           Comorbidities           CHF         170/936 (18.1)         78 /365 (21.4)           Cardiac arrhythmias         212/936 (22.6)         110/365 (30.1)           Valvular disease         53/936 (57.)         30/365 (82.2)           Hypertension         143/936 (15.3)         56/365 (15.3)           Diabetes         260/936 (27.8)         119/365 (32.6)           Neurological condition         139/936 (14.9)         46/365 (12.6)           Chronic pulmonary condition         215/936 (23.0)         88/365 (24.1)           Renal failure         160/936 (17.1)         75/365 (20.5)           Liver condition         95/936 (10.1)         50/365 (13.7)           Severity of illness           APACHE III         89 (77-103)         89 (75-103)           MAP mmHg         82 (76-91)         89 (75-91)           SpO <sub>2</sub> , %         98 (96-99)         38 (96-99)           Temperature, "C         30 (36.4-37.5)         36,7 (36.1-37.3)           Laboratory in the beginning of ventilation         736 (72.8-742) <td< td=""><td>• ,</td><td></td><td></td><td></td></td<>	• ,			
White         647/936 (69.1)         223 / 365 (61.1)           Black         85/936 (9.1)         31 / 365 (8.5)           Other         204 / 936 (21.8)         111 / 365 (30.4)           Comorbidities         CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 505 (53.5)           Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 366 (20.5)           Everity of illness         Value         Value           APACHE III         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         82 (76-91)         83 (76-91)           MAP, mmHg         82 (76-91)         83 (76-91)           SpO <sub>2</sub> , %         98 (96-99)         98 (96-99)           Temperature, °C         37 (3 (28-3.4)         7,34 (7.26-7.41)           PaO <sub>2</sub> / FlO <sub>2</sub> , mmHg         238 (15	~	.0, 550 (1.5)	3, 363 ()	0.005
Black Other         85 / 936 (9.1)         31 / 365 (8.5)           Other         204 / 936 (21.8)         111 / 365 (30.4)           Comorbidities         TO / 936 (18.1)         78 / 365 (21.4)           CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Liver condition         95 / 936 (10.1)         50 / 365 (13.7)           Severity of illness         4         48 / 365 (24.1)           APACHE III         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         89 (77-103)         89 (75-103)           MAP, mmHg         82 (76-91)         83 (76-91)         89 (96-99)           Temperature, "C         30 (364-375)         36 (736.1-37.3)           Laboratory in the begi		647 / 936 (69.1)	223 / 365 (61.1)	
Other         204/936 (21.8)         111/365 (30.4)           Comorbidities           CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (5.7)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Liver condition         95 / 936 (10.1)         75 / 365 (20.5)           Severity of illness         4         4PACHE III         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         89 (77-103)         89 (75-103)         89 (75-103)           MAP, mmHg         80 (70-91)         80 (76-91)         80 (76-91)           SpO <sub>2</sub> , %         98 (96-99)         80 (96-99)         80 (96-99)           Temperature, °C         37 (36 (728-742)         7.34 (726-741)         7.9 (68-88)           PaCO <sub>2</sub> , rmHg         7.36 (728-742)         7.				
Comorbidities         CHF         170 / 936 (18.1)         78 / 365 (21.4)           Cardiac arrhythmias         212 / 936 (22.6)         110 / 365 (30.1)           Valvular disease         53 / 936 (27.9)         30 / 365 (8.2)           Hypertension         143 / 936 (15.3)         56 / 365 (15.3)           Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Liver condition         51 (38-69)         65 (50-85)           Severity of illness         8         8           APACHE III         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         89 (77-103)         89 (75-103)           MAP, mmHg         89 (77-913)         89 (75-103)           SpO <sub>2</sub> , %         98 (96-99)         98 (96-99)           Temperature, °C         37.0 (364-37.5)         36 (73.61-37.3)           Laboratory in the beginning of ventilation         19 (36 (22-30)         40 (34-49)           Second day of ventilation parameters         13 (32-334)         40 (34-49)           Seco				
CHF       170 / 936 (18.1)       78 / 365 (21.4)         Cardiac arrhythmias       212 / 936 (22.6)       110 / 365 (30.1)         Valvular disease       53 / 936 (5.7)       30 / 365 (8.2)         Hypertension       143 / 936 (15.3)       56 / 365 (15.3)         Diabetes       260 / 936 (27.8)       119 / 365 (32.6)         Neurological condition       139 / 936 (14.9)       46 / 365 (12.6)         Chronic pulmonary condition       215 / 936 (33.0)       88 / 365 (24.1)         Renal failure       160 / 936 (17.1)       75 / 365 (20.5)         Liver condition       95 / 936 (10.1)       50 / 365 (13.7)         Severity of illness       3       48 / 69.9       65 (50-85)         Vital signs in the beginning of ventilation       89 (77-103)       89 (75-103)         MAP, mmHg       82 (76-91)       83 (76-91)       83 (76-91)         SpO <sub>2.9</sub> %       98 (96-99)       98 (96-99)       98 (96-99)         Temperature, °C       37.0 (364-37.5)       367 (36.1-37.3)         Laboratory in the beginning of ventilation       736 (728-742)       7.34 (7.26-7.41)         PaO <sub>2.7</sub> FiO <sub>2.9</sub> mmHg       238 (152-351)       213 (132-334)         Paccond day of ventilation parameters       7.9 (6.8-8.8)         Tidal volume, ml/kg PBW       <		2017 330 (21.0)	1117 303 (30.1)	
Cardiac arrhythmias       212/936 (22.6)       110/365 (30.1)         Valvular disease       53/936 (5.7)       30/365 (8.2)         Hypertension       143/936 (15.3)       56/365 (15.3)         Diabetes       260/936 (27.8)       119/365 (32.6)         Neurological condition       139/936 (14.9)       46/365 (12.6)         Chronic pulmonary condition       215/936 (32.0)       88/365 (24.1)         Renal failure       160/936 (17.1)       75/365 (20.5)         Liver condition       95/936 (10.1)       50/365 (13.7)         Severity of illness       4       46/565 (30.7)         APACHE III       51 (38-69)       65 (50-85)         Vital signs in the beginning of ventilation       89 (77-103)       89 (75-103)         MAP, mmHg       82 (76-91)       83 (76-91)       83 (76-91)         SpO <sub>2</sub> ,%       98 (96-99)       98 (96-99)       98 (96-99)       98 (96-99)       36.7 (36.1-37.3)         Laboratory in the beginning of ventilation       PH       7.36 (7.28-7.42)       7.34 (7.26-7.41)       9.20 (2.27)         PaC <sub>Q2</sub> , FinO <sub>2</sub> , mmHg       238 (152-351)       213 (132-334)       9.20 (2.27)         Second day of ventilation parameters       7.9 (6.8-8.8)       7.9 (6.8-8.8)         Tidal volume, ml/kg PBW       7 (5-10		170 / 936 (18 1)	78 / 365 (21 4)	0.186
Valvular disease       53 / 936 (5.7)       30 / 365 (8.2)         Hypertension       143 / 936 (15.3)       56 / 365 (15.3)         Diabetes       260 / 936 (27.8)       119 / 365 (32.6)         Neurological condition       139 / 936 (14.9)       46 / 365 (12.6)         Chronic pulmonary condition       215 / 936 (23.0)       88 / 365 (24.1)         Renal failure       160 / 936 (17.1)       75 / 365 (20.5)         Liver condition       59 / 936 (10.1)       50 / 365 (13.7)         Severity of illness       4PACHE III       51 (38-69)       65 (50-85)         Vital signs in the beginning of ventilation       89 (77-103)       89 (75-103)         MAP, mmHg       82 (76-91)       83 (76-91)         SpO <sub>2</sub> , %       98 (96-99)       98 (96-99)         Temperature, *C       37.0 (36.4-37.5)       36.7 (36.1-37.3)         Laboratory in the beginning of ventilation       7 34 (7.26-7.41)         PAO <sub>2</sub> / FiO <sub>2</sub> , mmHg       7.36 (7.28-7.42)       7.34 (7.26-7.41)         PaO <sub>2</sub> / FiO <sub>2</sub> , mmHg       38 (152-351)       213 (132-334)         Second day of ventilation parameters       7 (5-10)       7 (5-10)         FIEP, cmH <sub>2</sub> O       7 (5-10)       7 (5-10)         PIP, cmH <sub>2</sub> O       24 (20-28)       26 (22-30)				0.005
Hypertension       143 / 936 (15.3)       56 / 365 (15.3)         Diabetes       260 / 936 (27.8)       119 / 365 (32.6)         Neurological condition       139 / 936 (14.9)       46 / 365 (12.6)         Chronic pulmonary condition       215 / 936 (23.0)       88 / 365 (24.1)         Renal failure       160 / 936 (17.1)       75 / 365 (20.5)         Liver condition       50 / 365 (10.1)       50 / 365 (13.7)         Severity of illness       APACHE III       51 (38-69)       65 (50-85)         Vital signs in the beginning of ventilation       89 (77-103)       89 (75-103)         MAP, mmHg       82 (76-91)       83 (76-91)         SpO <sub>2</sub> , %       98 (96-99)       98 (96-99)         Temperature, °C       37.0 (36.4-37.5)       36.7 (36.1-37.3)         Laboratory in the beginning of ventilation       y       7.34 (7.26-7.41)         PAO <sub>2</sub> , fi <sub>1</sub> / <sub>2</sub> , mmHg       238 (152-351)       213 (132-334)         PaCO <sub>2</sub> , mmHg       238 (152-351)       213 (132-334)         PacO <sub>2</sub> , mmHg       7.8 (6.8-8.8)       7.9 (6.8-8.8)         PEEP, cmH <sub>2</sub> O       7 (5-10)       7 (5-10)         PIR, cmH <sub>2</sub> O       24 (20-28)       26 (22-30)         Respiratory rate, bpm       20 (17-23)       21 (18-24)	*			0.090
Diabetes         260 / 936 (27.8)         119 / 365 (32.6)           Neurological condition         139 / 936 (14.9)         46 / 365 (12.6)           Chronic pulmonary condition         215 / 936 (23.0)         88 / 365 (24.1)           Renal failure         160 / 936 (17.1)         75 / 365 (20.5)           Liver condition         95 / 936 (10.1)         50 / 365 (13.7)           Severity of illness         36 (50.8)         36 (50.8)           APACHE III         51 (38-69)         65 (50-85)           Vital signs in the beginning of ventilation         89 (77-103)         89 (75-103)           MAP, mmHg         82 (76-91)         83 (76-91)         83 (76-91)           SpO2, %         98 (96-99)         98 (96-99)         98 (96-99)           Temperature, °C         37.0 (36.4-37.5)         36.7 (36.1-37.3)         36.7 (36.1-37.3)           Laboratory in the beginning of ventilation         7.36 (7.28-7.42)         7.34 (7.26-7.41)         7.36 (7.28-7.42)         7.34 (7.26-7.41)           PaO2 / FiO2, mmHg         238 (152-351)         213 (132-334)         40.34-49           Second day of ventilation parameters         7.9 (6.8-8.8)         7.9 (6.8-8.8)           PEEP, cmH <sub>2</sub> O         7 (5-10)         7 (5-10)         7 (5-10)           PIP, cmH <sub>2</sub> O         24 (2			, ,	0.977
Neurological condition       139/936 (14.9)       46/365 (12.6)         Chronic pulmonary condition       215/936 (23.0)       88/365 (24.1)         Renal failure       160/936 (17.1)       75/365 (20.5)         Liver condition       95/936 (10.1)       50/365 (13.7)         Severity of illness         APACHE III       51 (38–69)       65 (50–85)         Vital signs in the beginning of ventilation       89 (77–103)       89 (75–103)         MAP, mmHg       82 (76–91)       83 (76–91)         SpO <sub>2</sub> , %       98 (96–99)       98 (96–99)         Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation       PH       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO <sub>2</sub> / FiO <sub>2</sub> , mmHg       238 (152–351)       213 (132–334)         PaCO <sub>2</sub> , mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH <sub>2</sub> O       7 (5–10)       7 (5–10)       7 (5–10)         PIP, cmH <sub>2</sub> O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)	•			0.085
Chronic pulmonary condition       215 / 936 (23.0)       88 / 365 (24.1)         Renal failure       160 / 936 (17.1)       75 / 365 (20.5)         Liver condition       95 / 936 (10.1)       50 / 365 (13.7)         Severity of illness       Fraction of the politic of				0.297
Renal failure       160 / 936 (17.1)       75 / 365 (20.5)         Liver condition       95 / 936 (10.1)       50 / 365 (13.7)         Severity of illness         APACHE III       51 (38–69)       65 (50–85)         Vital signs in the beginning of ventilation         Heart rate, bpm       89 (77–103)       89 (75–103)         MAP, mmHg       82 (76–91)       83 (76–91)         SpO <sub>2</sub> , %       98 (96–99)       98 (96–99)         Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation         pH       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO <sub>2</sub> / FiO <sub>2</sub> , mmHg       238 (152–351)       213 (132–334)         PaCO <sub>2</sub> , mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters         Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH <sub>2</sub> O       7 (5–10)       7 (5–10)         PIP, cmH <sub>2</sub> O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)				0.662
Liver condition       95 / 936 (10.1)       50 / 365 (13.7)         Severity of illness       51 (38–69)       50 / 365 (13.7)         APACHE III       51 (38–69)       65 (50–85)         Vital signs in the beginning of ventilation       89 (77–103)       89 (75–103)         Heart rate, bpm       89 (76–91)       83 (76–91)       83 (76–91)         SpO <sub>2</sub> , %       98 (96–99)       98 (96–99)       98 (96–99)         Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation       7.34 (7.26–7.41)       7.34 (7.26–7.41)         PAO <sub>2</sub> / FiO <sub>2</sub> , mmHg       238 (152–351)       213 (132–334)       40 (34–49)         Second day of ventilation parameters       11 (37–49)       40 (34–49)         Second day of ventilation parameters       7.9 (68–8.8)       7.9 (68–8.8)         PEEP, cmH <sub>2</sub> O       7 (5–10)       7 (5–10)       7 (5–10)         PIP, cmH <sub>2</sub> O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)	· · · · · · · · · · · · · · · · · · ·			0.146
Severity of illness       APACHE III       51 (38–69)       65 (50–85)         Vital signs in the beginning of ventilation       Wital signs in the beginning of ventilation         Heart rate, bpm       89 (77–103)       89 (75–103)         MAP, mmHg       82 (76–91)       83 (76–91)         \$pO <sub>2</sub> , %       98 (96–99)       98 (96–99)         Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation       pH       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO <sub>2</sub> / FiO <sub>2</sub> , mmHg       238 (152–351)       213 (132–334)         PaCO <sub>2</sub> , mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH <sub>2</sub> O       7 (5–10)       7 (5–10)       7 (5–10)         PIP, cmH <sub>2</sub> O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)				0.068
APACHE III       51 (38–69)       65 (50–85)         Vital signs in the beginning of ventilation         Heart rate, bpm       89 (77–103)       89 (75–103)         MAP, mmHg       82 (76–91)       83 (76–91)         SpO <sub>2</sub> , %       98 (96–99)         Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation         pH       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO <sub>2</sub> / FiO <sub>2</sub> , mmHg       238 (152–351)       213 (132–334)         PaCO <sub>2</sub> , mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters         Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH <sub>2</sub> O       7 (5–10)       7 (5–10)         PIP, cmH <sub>2</sub> O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)		33 / 330 (10.1)	307 303 (13.7)	0.000
Vital signs in the beginning of ventilation         Heart rate, bpm       89 (77–103)       89 (75–103)         MAP, mmHg       82 (76–91)       83 (76–91)         \$p0_2, %       98 (96–99)       98 (96–99)         Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO2 / FiO2, mmHg       238 (152–351)       213 (132–334)         PaCO2, mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH2O       7 (5–10)       7 (5–10)       7 (5–10)         PIP, cmH2O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)		51 (38–69)	65 (50–85)	< 0.001
Heart rate, bpm89 (77–103)89 (75–103)MAP, mmHg82 (76–91)83 (76–91)SpO2, %98 (96–99)98 (96–99)Temperature, °C37.0 (36.4–37.5)36.7 (36.1–37.3)Laboratory in the beginning of ventilation pH7.36 (7.28–7.42)7.34 (7.26–7.41)PaO2 / FiO2, mmHg238 (152–351)213 (132–334)PaCO2, mmHg41 (37–49)40 (34–49)Second day of ventilation parametersTidal volume, ml/kg PBW7.8 (6.8–8.8)7.9 (6.8–8.8)PEEP, cmH2O7 (5–10)7 (5–10)PIP, cmH2O24 (20–28)26 (22–30)Respiratory rate, bpm20 (17–23)21 (18–24)		31 (30 03)	03 (30 03)	( 0.001
MAP, mmHg82 (76-91)83 (76-91)SpO2, %98 (96-99)98 (96-99)Temperature, °C37.0 (36.4-37.5)36.7 (36.1-37.3)Laboratory in the beginning of ventilation pH7.36 (7.28-7.42)7.34 (7.26-7.41)PaO2/FiO2, mmHg238 (152-351)213 (132-334)PaCO2, mmHg41 (37-49)40 (34-49)Second day of ventilation parametersTidal volume, ml/kg PBW7.8 (6.8-8.8)7.9 (6.8-8.8)PEEP, cmH2O7 (5-10)7 (5-10)PIP, cmH2O24 (20-28)26 (22-30)Respiratory rate, bpm20 (17-23)21 (18-24)		89 (77–103)	89 (75–103)	0.496
SpO₂,%       98 (96–99)       98 (96–99)         Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation       T.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO₂ / FiO₂, mmHg       238 (152–351)       213 (132–334)         PaCO₂, mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH₂O       7 (5–10)       7 (5–10)         PIP, cmH₂O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)	·			0.465
Temperature, °C       37.0 (36.4–37.5)       36.7 (36.1–37.3)         Laboratory in the beginning of ventilation       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PAO2 / FiO2, mmHg       238 (152–351)       213 (132–334)         PaCO2, mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH2O       7 (5–10)       7 (5–10)       7 (5–10)         PIP, cmH2O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)				0.016
Laboratory in the beginning of ventilation         pH       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO2 / FiO2, mmHg       238 (152–351)       213 (132–334)         PaCO2, mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH2O       7 (5–10)       7 (5–10)       7 (5–10)         PIP, cmH2O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)	-		· · ·	< 0.001
pH       7.36 (7.28–7.42)       7.34 (7.26–7.41)         PaO2 / FiO2, mmHg       238 (152–351)       213 (132–334)         PaCO2, mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH2O       7 (5–10)       7 (5–10)       7 (5–10)         PIP, cmH2O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)	'	37.0 (30.1 37.3)	30.7 (30.1 37.3)	( 0.001
$\begin{array}{llllllllllllllllllllllllllllllllllll$	, , , , , , , , , , , , , , , , , , , ,	7 36 (7 28–7 42)	7 34 (7 26–7 41)	0.002
PaCO <sub>2</sub> , mmHg       41 (37–49)       40 (34–49)         Second day of ventilation parameters       7.8 (6.8–8.8)       7.9 (6.8–8.8)         Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH <sub>2</sub> O       7 (5–10)       7 (5–10)         PIP, cmH <sub>2</sub> O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)				0.047
Second day of ventilation parameters         Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH2O       7 (5–10)       7 (5–10)         PIP, cmH2O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)				0.059
Tidal volume, ml/kg PBW       7.8 (6.8–8.8)       7.9 (6.8–8.8)         PEEP, cmH <sub>2</sub> O       7 (5–10)       7 (5–10)         PIP, cmH <sub>2</sub> O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)	_	11 (37 13)	10 (3 1 12)	0.033
PEEP, cmH $_2$ O       7 (5–10)       7 (5–10)         PIP, cmH $_2$ O       24 (20–28)       26 (22–30)         Respiratory rate, bpm       20 (17–23)       21 (18–24)		7.8 (6.8–8.8)	79 (68–88)	0.880
PIP, cmH <sub>2</sub> O 24 (20–28) 26 (22–30) Respiratory rate, bpm 20 (17–23) 21 (18–24)	•			0.016
Respiratory rate, bpm 20 (17–23) 21 (18–24)	_			< 0.001
	_	, ,		< 0.001
	inute ventilation, L/min	9.2 (7.7–11.1)	9.6 (8.6–11.7)	0.009
MP, J/min 13.5 (10.2–18.4) 14.7 (11.3–19.9)				< 0.007
norMP, 10 <sup>-3</sup> J/min/kg 222.1 (161.3–288.0) 245.4 (183.8–333.4)				< 0.001

Data are median (interquartile range) or No / Total (%)

BMI body mass index, PBW predicted body weight, CHF congestive heart failure, bpm beats per minute, SpO<sub>2</sub> pulse oximetry, MAP mean arterial blood pressure, FiO<sub>2</sub> inspired fraction of oxygen, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure, MP mechanical power, norMP mechanical power normalized to predicted body weight

Zhu et al. BMC Anesthesiology (2021) 21:278 Page 5 of 9

(n = 325); from  $166.5 \times 10^{-3}$  J/min/kg to  $226.4 \times 10^{-3}$  J/ min/kg, quartile 2 (n = 325); from  $226.5 \times 10^{-3}$  J/min/ kg to  $300.9 \times 10^{-3} \text{ J/min/kg}$ , quartile 3, (n = 325); quartile greater than  $301.0 \times 10^{-3} \text{ J/min/kg}$ (n = 326). The clinical outcomes of patients in various groups were summarized in Table 2. ICU mortality (72 [22.2], 91 [28.0], 85 [26.2], 117 [35.9], respectively), ICU length of stay (ICU\_LOS: 7.7 [4.9-11.5], 8.1 [5.4-12.4], 9.7 [6.1–14.6], 9.8 [6.0–16.8], respectively), and ventilator-free days at day 28 (VFD\_28: 21.5 [0-24.7], 21.1 [0-24.4], 19.6 [0-23.4], 15.6 [0-21.8], respectively) showed statistically significant difference (p < 0.05, all). However, there was no evidence that 30-day mortality and 90-day mortality between the groups was statistically different (p > 0.05).

Figure 2 illustrates the results of the univariate and multivariate analysis of the primary outcome. Crude outcome shows that High norMP was associated with increased ICU mortality (OR = 1.22, 95% CI 1.09–1.36, p < 0.001). In addition, norMP in the second 24h still had a strong correlation with increased ICU mortality even after adjustment for covariates (OR = 1.33, 95% CI 1.16–1.52, p < 0.001).

Figure 3 illustrates the results of the multivariate analysis of the 30-day mortality, 90-day mortality, ICU\_LOS, and VFD\_28. norMP in the second 24h of ventilation was also associated with ICU length of stay and the number of ventilator-free days (Fig. 3b). However, there was no association between norMP and 30-day mortality or 90-day mortality (Fig. 3a).


In the subgroup analysis (Fig. 4), regardless of the Vt level, high norMP was associated with ICU mortality

**Table 2** Clinical outcomes of subjects by the quartile of the norMP

	norMP, 10 <sup>-3</sup> J/min/kg				
	quartile 1 < 166.4	quartile 2 166.4–226.4	quartile 3 226.5–300.9	quartile 4 ≥301.0	
ICU mortality	72 (22.2)	91 (28.0)	85 (26.2)	117 (35.9)	0.001
30-day mortality	102 (31.4)	105 (32.3)	104 (32.0)	123 (37.7)	0.284
90-day mortality	119 (36.6)	122 (37.5)	123 (37.8)	138 (42.3)	0.442
ICU_LOS, day	7.7 (4.9–11.5)	8.1 (5.4–12.4)	9.7 (6.1–14.6)	9.8 (6.0-16.8)	< 0.001
VFD_28, day	21.5 (0-24.7)	21.1 (0-24.4)	19.6 (0-23.4)	15.6 (0-21.8)	< 0.001


Data are median (interquartile range) or No / Total (%)

norMP mechanical power normalized to predicted body weight, ICU intensive care unit, LOS length of stay, VFD\_28 Ventilator-free days at day 28




**Fig. 2** norMP in the second 24h of ventilation and ICU mortality. Model 1 was adjusted for the confounders age, sex and ethnicity. Model 2 was adjusted for the confounders, including age, sex, ethnicity, BMI, admission type, comorbidities, APACHE, heart rate, MAP, SpO $_2$ , temperature, pH, PaO $_2$  / FiO $_2$ , PaCO $_2$ . The odds ratio represents the odds of death per quartile increase in norMP: mechanical power normalized to predicted body weight

Zhu et al. BMC Anesthesiology (2021) 21:278 Page 6 of 9



**Fig. 3** norMP in the second day of ventilation and secondary outcomes. **a** Odds ratio represents the odds of death per quartile increase in norMP. **b** Effect estimates and 95% confidence interval from the multivariable linear regression for VFD\_28 and ICU\_los. Effect estimate refers to the change in the outcome variable per quartile increase in norMP. norMP: mechanical power normalized to predicted body weight; VFD\_28: Ventilator-free days at day 28; ICU: intensive care unit; LOS: length of stay



**Fig. 4** Subgroup analysis of the association between norMP and ICU mortality according to different tidal volumes and airway pressure levels. The odds ratio represents the odds of death per quartile increase in norMP. norMP: mechanical power normalized to predicted body weight; Vt: tidal volume; PIP: peak inspiratory pressure

(OR=1.31, 95% CI 1.09–1.57, p=0.004; OR=1.32, 95% CI 1.08–1.62, p=0.008, respectively). The analysis revealed (Fig. 4) that high norMP was associated with ICU mortality only in patients with PIP < 30 cmH<sub>2</sub>O (OR=1.18, 95% CI 1.01–1.38, p=0.034). Our results also (eTable 1) showed the PEEP levels were significantly lower for patients with low PIP levels (5 [5–8.5]; p=0.004) than for those with high PIP levels (10 [7.5–15], p<0.001).

# **Discussion**

The essential findings of this research can be summarized as follows: (a) norMP during the second 24h of ventilation was independently correlated with increased ICU

mortality of critically ill patients, who received invasive ventilation for more than 48 h; (b) increased norMP was independently correlated with a longer ICU stay, a lower number of ventilator-free days and alive at day 28; and (c) high norMP was associated with ICU mortality regardless of Vt, but high norMP was associated with ICU mortality in patients with low PIP only.

In invasive ventilation, a lung-protection ventilation strategy that provides adequate gas exchange while minimizing VILI should be used [22, 23]. VILI has been primarily associated with excessive pressure, excessive volume, and atelectasis [8, 24]. Therefore, mechanical ventilation strategies to reduce VILI have sought to

Zhu et al. BMC Anesthesiology (2021) 21:278

optimize all potential determinants including respiratory rate, tidal volume, and PEEP [17, 25-29]. While individual ventilator parameters have been extensively studied in previous research, few studies have considered these factors comprehensively. One study has shown that MP can be computed from its components: Vt, plateau pressure, flow, PEEP, and RR [7]. Since MP is a composite of these variables, it may be a candidate variable to improve prediction of clinical outcomes (such as mortality) [11]. The authors believe that norMP is superior to MP because the effects of MP were proportional to their involvement in total lung function size. Given similar mechanical power values, different energies will be delivered according to different ventilated lung surfaces. Hong et al. [30] have demonstrated that the effect size of MP differs across subgroups of acute respiratory failure (ARF) populations. The effect size of MP on mortality is the smallest in class 1 (baseline) and the largest in class 3 (refractory respiratory failure). The heterogeneity of patients with ARF supports the hypothesis that the effect of MP on VILI is dependent on the functional lung size. Additionally, a previous study [12], normalizing the mechanical power to the predicted body weight as a proxy for lung size, demonstrated that norMP had the highest area under the receiver operating characteristic among all ventilator parameters, and it had a more accurate prediction of in-hospital mortality. Similar to a previous study, the results of this analysis proved that norMP was a predictor of poor outcomes in ICU patients undergoing invasive ventilation.

Since the two important factors of ventilator parameters are tidal volume and airway pressure, we evaluated the effect of norMP on the prognosis of patients with different tidal volumes and airway pressure levels. In line with our hypothesis, we discovered that high MP was correlated with ICU mortality, even when Vt was low. This suggested that norMP added more information aside from the volume. Our research also demonstrated that a high norMP was associated with ICU mortality in patients with low PIP only. We propose a possible explanation for this finding. Our results showed that PEEP levels were higher in the group of patients with high PIP levels than in their counterpart. Patients with high PIP levels may be more severely ill, as sicker patients may be default be receiving higher PEEP levels. This may explain why low norMP was not associated with decreased ICU mortality in patients with high PIP. The majority of mechanical power in patients with higher levels of PEEP may be secondary to the applied PEEP. This further emphasizes the need to consider the PEEP component in the analysis. We failed to do a simple sensitivity analysis taking out the PEEP (focused on patients without PEEP), because the sample became very small in this situation. However, we have performed an analysis to determine the relationship between norMP and ICU mortality according to the different level of PEEP. Considering this analysis complicated the results so much, we decided not to report. Therefore, further investigations (including clinical trials) are necessary to explore the relationship between norMP and mortality in patients without applied PEEP.

Page 7 of 9

These findings suggested that norMP might be a useful marker to predict clinical outcomes because it combines the effects of different ventilator parameters. Modifying a single parameter has little effect on the amount of energy transmitted to the lung tissue, and it does not always protect the lungs [31]. According to the concept of protective ventilation, a decrease in volume necessitates an increase in the respiratory rate to offset the loss of minute volume. A higher respiratory rate leads to higher norMP. Therefore, volume reduction does not result in profit, according to our current study and previous studies [32, 33]. In the future, ventilators directly displaying the norMP applied to the respiratory system will promote lung protection. The caregiver can titrate ventilation to reduce the amount of energy supplied to the lung tissue.

In addition to not considering the PEEP component in the analysis, our current analysis had some limitations. First, in order to determine patients with more serious illnesses and ample exposure time, only patients who underwent invasive ventilation for at least 48 h were selected. However, the current findings cannot be generalized for patients who were extubated or died within the first 48 h. Second, norMP was calculated only once and not during the ICU stay. Therefore, it did not accurately represent the temporal changes in norMP administered to the patient. Third, since the datasets used in this study were from publicly available data, the airway pressure may not have been collected under consistent standard conditions. Such is the case in patients without spontaneous breathing efforts. Finally, it was difficult to quantify functional lung size. In the present study, we indirectly described the functional lung size through PBW. However, other conditions leading to decreased functional lung size, such as ARF and ARDS, were not considered. In the future, further studies investigating normalizing MP to respiratory system compliance or lung volume determined using CT [34] are necessary in subgroup of patients with ARF or ARDS. In addition, it is hard to recognize ARF patients without lung injury and those with ventilation failure caused by neuromuscular dysfunction in MIMIC III. Thus, this issue was not analyzed in this study.

Zhu et al. BMC Anesthesiology (2021) 21:278 Page 8 of 9

#### **Conclusions**

High norMP is independently correlated with increased ICU mortality and many other clinical outcomes in critically ill patients who undergo invasive ventilation for at least 48 h. Due to the ease with which norMP can be determined using ventilator parameters, monitoring norMP can help predict the early outcome of ICU patients undergoing invasive ventilation.

#### Abbreviations

BMI: Body mass index; PBW: Predicted body weight; CHF: Congestive heart failure; bpm: Beats per minute; SpO<sub>2</sub>: Pulse oximetry; MAP: Mean arterial blood pressure; FiO<sub>2</sub>: Inspired fraction of oxygen; PEEP: Positive end-expiratory pressure; PIP: Peak inspiratory pressure; RR: Respiratory rate; Vt: Tidal volume; MP: Mechanical power; norMP: Mechanical power normalized to predicted body weight; ICU: Intensive care unit; LOS: Length of stay; VFD\_28: Ventilator-free days at day 28; ARF: Acute respiratory failure.

# **Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12871-021-01497-1.

Additional file 1: eTable 1. Comparisons of PEEP between different PIP level

#### Acknowledgements

Not applicable.

#### Authors' contributions

Yanhong Zhu and Xiaofeng Jiang designed this study. Shuai Zhen extracted the Data. Yanhong Zhu analyzed the data and drafted the manuscript. Xiaofeng Jiang and Wenyong Peng critically revised the manuscript. All authors read and approved the final manuscript.

# Funding

No funding was obtained for this study.

#### Availability of data and materials

The datasets of the current study are available from the corresponding author on reasonable request.

# **Declarations**

#### Ethics approval and consent to participate

The datasets used for the current study come from [MIMIC-III ver.1.4] repository. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This project was both approved by BIDMC and the institutional review boards of Massachusetts Institute of Technology (MIT) (certification number: 9322422) and individual consent for this retrospective analysis was waived.

#### Consent for publication

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Department of Anesthesiology, The First People's Hospital of Pinghu, Zhejiang, China. <sup>2</sup>Department of Anesthesiology, Jinhua Municipal Central Hospital, 365 Renmin East Road, Jinhua, Zhejiang, China.

Received: 20 June 2021 Accepted: 31 October 2021 Published online: 10 November 2021

#### References

- Cruz FF, Ball L, Rocco P, et al. Ventilator-induced lung injury during controlled ventilation in patients with acute respiratory distress syndrome: less is probably better. Expert Rev Respir Med. 2018;12(5):403–14.
- Silva PL, Ball L, Rocco PA, et al. Power to mechanical power to minimize ventilator-induced lung injury? Intensive Care Med Exp. 2019;7(Suppl 1):38
- Silva PL, Negrini D, Rocco PR. Mechanisms of ventilator-induced lung injury in healthy lungs. Best Pract Res Clin Anaesthesiol. 2015;29(3):301–13.
- Beitler JR, Malhotra A, Thompson BT. Ventilator-induced lung injury. Clin Chest Med. 2016;37(4):633–46.
- Chiumello D, Pristine G, Slutsky AS. Mechanical ventilation affects local and systemic cytokines in an animal model of acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160(1):109–16.
- Gattinoni L, Carlesso E, Cadringher P, et al. Physical and biological triggers of ventilator-induced lung injury and its prevention. Eur Respir J Suppl. 2003;47:15s-25s
- Gattinoni L, Tonetti T, Cressoni M, et al. Ventilator-related causes of lung injury: the mechanical power. Intensive Care Med. 2016;42(10):1567–75.
- 8. Tonetti T, Vasques F, Rapetti F, et al. Driving pressure and mechanical power: new targets for VILI prevention. Ann Transl Med. 2017;5(14):286.
- Cressoni M, Gotti M, Chiurazzi C, et al. Mechanical Power and Development of Ventilator-induced Lung Injury. Anesthesiology. 2016;124(5):1100–8.
- Marini JJ, Rocco PRM, Gattinoni L. Static and dynamic contributors to ventilator-induced lung injury in clinical practice. Pressure, energy, and power. Am J Respir Crit Care Med. 2020;201(7):767–74.
- Neto AS, Deliberato RO, Johnson AEW, et al. Mechanical power of ventilation is associated with mortality in critically ill patients: an analysis of patients in two observational cohorts. Intensive Care Med. 2018;44(11):1914–22.
- 12. Zhang Z, Zheng B, Liu N, et al. Mechanical power normalized to predicted body weight as a predictor of mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 2019;45(6):856–64.
- Linares-Perdomo O, East TD, Brower R, et al. Standardizing predicted body weight equations for mechanical ventilation tidal volume settings. Chest. 2015;148(1):73–8.
- 14. Coppola S, Caccioppola A, Froio S, et al. Effect of mechanical power on intensive care mortality in ARDS patients. Crit Care. 2020;24(1):246.
- Johnson AE, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:160035.
- van Meenen DA-O, Serpa Neto A, Paulus F, et al. The predictive validity for mortality of the driving pressure and the mechanical power of ventilation. Intensive Care Med Exp. 2020;8(Suppl 1):60.
- Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8.
- Salluh JI, Soares M. ICU severity of illness scores: APACHE, SAPS and MPM. Curr Opin Crit Care. 2014;20(5):557–65.
- Zhang Z, Chen K, Chen L. APACHE III outcome prediction in patients admitted to the intensive care unit with Sepsis associated acute lung injury. PLoS One. 2015;10(9):e0139374.
- Serpa Neto A, Schultz MJ, Slutsky AS. Current concepts of protective ventilation during general anaesthesia. Swiss Med Wkly. 2015;145:w14211.
- 21. Gattinoni L, Marini JJ, Collino F, et al. The future of mechanical ventilation: lessons from the present and the past. Crit Care. 2017;21(1):183.
- Chiumello D, Brochard L, Marini JJ, et al. Respiratory support in patients with acute respiratory distress syndrome: an expert opinion. Crit Care. 2017;21(1):240.
- Coppola S, Caccioppola A, Froio S, et al. Dynamic hyperinflation and intrinsic positive end-expiratory pressure in ARDS patients. Crit Care. 2019;23(1):375.
- 24. Albaiceta GM, Blanch L. Beyond volutrauma in ARDS: the critical role of lung tissue deformation. Crit Care. 2011;15(2):304.

Zhu et al. BMC Anesthesiology (2021) 21:278 Page 9 of 9

- Gattinoni L, Marini JJ, Pesenti A, et al. The "baby lung" became an adult. Intensive Care Med. 2016;42(5):663–73.
- 26. Curley GF, Laffey JG, Zhang H, et al. Biotrauma and ventilator-induced lung injury: clinical implications. Chest. 2016;150(5):1109–17.
- Amato MB, Meade MO, As S, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747–55.
- 28. Putensen C, Theuerkauf N, Zinserling J, et al. Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury. Ann Intern Med. 2009;151(8):566–76.
- Meade MO, Cook DJ, Guyatt GH, et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2008;299(6):637–45.
- Hong Y, Chen L, Pan Q, et al. Individualized mechanical power-based ventilation strategy for acute respiratory failure formalized by finite mixture modeling and dynamic treatment regimen. EClinicalMedicine. 2021;36:100898.

- 31. Gattinoni L, Tonetti T, Quintel M. Intensive care medicine in 2050: ventilator-induced lung injury. Intensive Care Med. 2018;44(1):76–8.
- Santos RS, Maia LA, Oliveira MV, et al. Biologic impact of mechanical power at high and low tidal volumes in experimental mild acute respiratory distress syndrome. Anesthesiology. 2018;128(6):1193–206.
- Marini JJ, Gattinoni L. Energetics and the root mechanical cause for ventilator-induced lung injury. Anesthesiology. 2018;128(6):1062–4.
- 34. Gattinoni L, Caironi P, Pelosi P, et al. What has computed tomography taught us about the acute respiratory distress syndrome? Am J Respir Crit Care Med. 2001;164(9):1701–11.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

# Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$  thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

**Learn more** biomedcentral.com/submissions

